Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 167 participants.
Also called NCT02968368
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 167 participants
- Sponsor
- Shield Therapeutics
- Registry
-
NCT02968368
-
- Other papers using this trial's data
- Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02968368. Randomized; quadruple masking; primary purpose treatment. Start 2016-12-01 (actual); primary completion 2018-01-18 (actual). Results posted on 2020-05-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
- Acronym
- AEGIS-CKD
- Condition
- Renal Insufficiency, Chronic
- Condition
- Iron-Deficiency Anemia
- Intervention (Drug)
- Ferric maltol
- Intervention (Other)
- Placebo
- Lead sponsor
- Shield Therapeutics
Record details
- Record id
cardio:ct-nct02968368- Content hash
b715c27e0c34df066ae154163dfbe39c02b5311f1ab2155463db378e384c0dc0